Tecartus Approved as First CAR T-Cell Therapy for Mantle Cell Lymphoma

The FDA approved the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) for ...

JULY 29, 2020